Decoding the DRB502:21 Allele: What It Means for Transplants
"A newly identified gene variant could improve outcomes in kidney and stem cell transplantation."
The world of transplant medicine is constantly evolving, with researchers working to refine the matching process between donors and recipients. A critical aspect of this is understanding the subtle variations in human leukocyte antigen (HLA) genes, which play a vital role in the immune system's ability to distinguish between self and non-self.
Recently, a team of scientists identified a novel HLA-DRB502 allele, named DRB502:21. This new allele carries a single nucleotide substitution compared to the more common DRB502:02:01 allele. The discovery, made during the HLA typing of two patients awaiting transplants, highlights the ongoing refinement of our understanding of genetic diversity and its implications for transplantation.
This article breaks down what the DRB502:21 allele is, why its identification is important, and what it could mean for individuals awaiting kidney or hematopoietic stem cell transplants.
Frequency and HLA Diversity
In a 2025 cohort, 554 individuals, or 8.8%, were identified as HLA-DRB1*15:03 positive; 48 of those individuals, representing 8.7% of the HLA-DRB1*15:03-positive group, carried the reported DRB5-associated finding. The IPD-IMGT/HLA Database lists 45,421 HLA alleles, including 14,527 HLA class II alleles, illustrating the breadth of variation relevant to high-resolution matching. A 2021 study reported 4 HLA-DRB3, 5 HLA-DRB4, and 3 HLA-DRB5 alleles in its analysis, while allele counts can vary by database and reporting date.
From Serology to High Resolution
HLA typing has progressed from serological methods to PCR-based and sequencing approaches. PCR-based methods can be rapid and require relatively little DNA, but the cited 2024 review notes that they may require sufficiently high-quality DNA. Traditional typing focused only on the antigen-recognition-site region can limit high-resolution genotype assignment, and serological methods resolve only a limited number of HLA alleles. These limitations help explain why transplantation decisions increasingly require more detailed molecular typing.
Documenting New DRB5 Alleles
The HLA-DRB5*02:35 allele, reported in 2023, differed from HLA-DRB5*02:02:01 by one nonsynonymous nucleotide substitution in exon 2. Earlier sequence-based typing work documented the identification of a new HLA-DRB5 allele, reflecting the gradual expansion of recognized variation at this locus. The Allele Frequency Net Database provides a dedicated search framework for DRB5 and related loci, showing how allele discovery and population-frequency cataloging became linked.
DRB502:21: A Tiny Change with Big Implications
The HLA-DRB5 gene is part of the major histocompatibility complex (MHC), a region of the human genome that is highly variable. This variability is crucial for the immune system, allowing it to recognize a wide range of foreign invaders. However, it also means that matching donors and recipients for transplantation can be challenging.
- The difference: The DRB502:21 allele has one nucleotide substitution compared to DRB502:02:01.
- Location of change: This substitution occurs at codon 203 in exon 4 of the HLA-DRB5 gene.
- Protein alteration: The change results in an isoleucine to valine substitution in the HLA-DRB5 protein.
A Novel Allele in Transplant Candidates
The 2018 characterization of HLA-DRB5*02:21 described it as a novel HLA-DRB5*02 allele. It was identified in two patients: one awaiting kidney transplantation and the other awaiting hematopoietic stem-cell transplantation. The report places the allele in a clinically relevant setting, but the supplied source does not establish how common it is or define a specific transplant outcome attributable to it.
Why Interpretation Can Be Difficult
HLA sequencing reports can contain allele nomenclature and interpretation issues, including ambiguous results that require careful review. High-resolution typing of HLA-DRB3, HLA-DRB4, and HLA-DRB5 is used in donor assessment to evaluate the presence of donor-specific antibodies in transplant patients. Educational material on HLA nomenclature also emphasizes that alleles sharing a broad designation, such as HLA-A*02, are not necessarily identical at higher resolution. These points caution against treating a partial or ambiguous label as a complete compatibility assessment.
Resolution and Concordance
A 2019 study of single-pass high-resolution HLA typing found concordant results for HLA class II loci including DRB1, DRB3, DRB4, DRB5, DQA1, DQB1, DPA1, and DPB1, except for 11 allele assignments among eight specimens. Long-read sequencing approaches are designed to resolve highly homologous, haplotype-phased, full-length genes without ambiguity. Organ-allocation conversion guidance separately maps DRB5*01 and DRB5*02 specificities, except null alleles, to the DR51 grouping. Together, these sources show that laboratory-level allele resolution and allocation-system categories are related but not interchangeable.
Looking Ahead: The Importance of Precise HLA Typing
The identification of the DRB502:21 allele underscores the importance of continuous refinement in HLA typing methods. As technology advances, researchers can identify increasingly subtle genetic variations that may impact transplant outcomes.
A Rare Finding With Clinical Relevance
The characterization of HLA-DRB5*02:21 reported the allele in two patients, one awaiting kidney transplantation and one awaiting hematopoietic stem-cell transplantation. This makes the finding relevant to transplant evaluation because it arose in patients being assessed for donor-organ or stem-cell treatment. However, the supplied report does not provide enough information to determine the allele's population frequency, independent clinical effect, or effect on transplant success. Its significance therefore depends on the complete HLA profile and clinical context rather than the allele name alone.
Growth in HLA Typing
Market projections suggest continued expansion of HLA typing technologies and services. One forecast estimates growth from USD 0.91 billion in 2026 to USD 1.78 billion by 2035, with a 7.65% compound annual growth rate. Another projects an increase from USD 1.39 billion in 2025 to USD 2.65 billion by 2036, with a 6.7% compound annual growth rate. Because these forecasts differ in their starting values, endpoints, and time periods, they should be viewed as projections rather than established outcomes.
Beyond a Single Allele
A DRB5*02:21 result is only one element of a broader transplant evaluation. Its practical meaning may depend on the patient's complete HLA profile, the available donor or organ, laboratory resolution, and clinical circumstances. Because transplant compatibility involves multiple interacting factors, the allele should not be interpreted as a standalone prediction of success or failure.
Immune Recognition and Patient Care
HLA-DRB5 is described as contributing to the fine-tuning of immune responses by influencing the repertoire of peptides presented to T cells. Research in multiple sclerosis genotyped 11 HLA genes in 477 patients and 954 comparison individuals, illustrating how HLA variation can be studied across patient groups. Other work reports that HLA polymorphisms may affect immune detection of malignant cells and the direction of T-cell elimination. These findings support the importance of precise HLA characterization while not proving that HLA-DRB5*02:21 itself causes a particular disease or transplant outcome.
The nucleotide sequence of the exons 2 to 5 of the new allele has been submitted to the GenBank database (Accession No. MH645229) and to the IPD-IMGT/HLA Database (Submission No. HWS10052823 and HWS10053373), ensuring this information is available to the broader scientific community.
For patients awaiting transplants, this discovery highlights the ongoing efforts to improve matching and minimize the risk of rejection. While the clinical significance of this specific allele remains to be fully elucidated, its identification represents another step forward in the quest for personalized and successful transplantation.